MedTrace Logo

JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness

NCT03728309 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2022-12-19

Study results available
· View outcomes & findings →

Summary

This is a pivotal study to collect safety and effectiveness data on JUVÉDERM VOLITE™ XC for improvement in skin smoothness of the cheeks in order to support FDA product approval.

Conditions

  • Skin Smoothness of the Cheeks

Interventions

DEVICE

JUVÉDERM VOLITE™ XC

Intradermal, needle in multiple microdepot injections across both cheeks.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • ALLERGAN, INC. · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2020-07-17
Completion
2020-07-17
FDA Device
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03728309 on ClinicalTrials.gov